S18-000003 (C008B-268473)

In VitroS18-000003 inhibits human and mouse RORγt-dependent transactivation, with IC 50 s of 0.029 and 0.34 μM respectively in cell-based GAL4 promoter reporter assays. S18-000003 (0.003-0.3 μM; 7 d) dose-dependently inhibits Th17 cell differentiation from human naive CD4 + T cells, with an IC 50 of 0.024 μM. S18-000003 (0.1-3 μM; 4 d) inhibits the differentiation of mouse Th17 cells from splenic naive CD4 + T cells, with an IC 50 of 0.20 μM. S18-000003 (0.03-1 μM; 3 d) reduces the IL-17 production in human PBMCs in a dose-dependent manner, and does not inhibit either the production of other cytokines (IL-2, IL-4, IL-10 and IFN-g) or cell proliferation. S18-000003 (0.1-3 μM; 3 d) reduces IL-17 and IL-22 production in PBMCs from psoriatic mice in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoS18-000003 (30-100 mg/kg; p.o.) inhibits IL-17 production in the skin of IL-23-treated mice in a dose-dependent manner . S18-000003 (0.1-8%; 100mL; topically administration once daily for 14 days) ameliorates psoriasis-like lesions in TPA-induced K14.Stat3C transgenic mice, and has little impact on the thymus. S18-000003 (0.5 mg/kg; i.v.) exhibits the half-life (3.2 h), AUC (1930 ng•h/mL), CL tot (4.33 mL/min/kg) and Vd ss in rats . S18-000003 (1 mg/kg; p.o.) exhibits the oral bioavailability (54.5%), C max (185 ng/mL), AUC (2110 ng•h/mL) and T max (4 h) in rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:RORγt <30 nM (IC 50 )

Specifications & Purity: In VitroS18-000003 inhibits human and mouse RORγt-dependent transactivation, with IC 50 s of 0.029 and 0.34 μM respectively in cell-based GAL4 promoter reporter assays. S18-000003 (0.003-0.3 μM; 7 d) dose-dependently inhibits Th17 cell differentiation from human naive CD4 + T cells, with an IC 50 of 0.024 μM. S18-000003 (0.1-3 μM; 4 d) inhibits the differentiation of mouse Th17 cells from splenic naive CD4 + T cells, with an IC 50 of 0.20 μM. S18-000003 (0.03-1 μM; 3 d) reduces the IL-17 production in human PBMCs in a dose-dependent manner, and does not inhibit either the production of other cytokines (IL-2, IL-4, IL-10 and IFN-g) or cell proliferation. S18-000003 (0.1-3 μM; 3 d) reduces IL-17 and IL-22 production in PBMCs from psoriatic mice in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoS18-000003 (30-100 mg/kg; p.o.) inhibits IL-17 production in the skin of IL-23-treated mice in a dose-dependent manner . S18-000003 (0.1-8%; 100mL; topically administration once daily for 14 days) ameliorates psoriasis-like lesions in TPA-induced K14.Stat3C transgenic mice, and has little impact on the thymus. S18-000003 (0.5 mg/kg; i.v.) exhibits the half-life (3.2 h), AUC (1930 ng•h/mL), CL tot (4.33 mL/min/kg) and Vd ss in rats . S18-000003 (1 mg/kg; p.o.) exhibits the oral bioavailability (54.5%), C max (185 ng/mL), AUC (2110 ng•h/mL) and T max (4 h) in rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:RORγt <30 nM (IC 50 )

Grade: Moligand™

Molecular Formula: C26H25F3N2O4S

Molecular Weight: 518.55

PubChem CID: 137796283

Isomeric SMILES: CCS(=O)(=O)C1=CC=C(C=C1)CC(=O)NC2=CC(=C(C=C2)C(C)(C)C(=O)NC3=C(C=C(C=C3)F)F)F

Storage Temperature: Store at -20°C

Shipped in: Ice chest + Ice pads

UPC:

41115700

Weight:

1.06 Ounces

HazmatClass:

Yes

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

S648830-100mg

Country of Origin:

China

CAS:

2068119-11-7

Product Size:

100mg

Harmonized Tariff Code:

2931.90.90